Mirum Pharmaceuticals Reports Results for Quarter Ended June 30, 2026

What Happened

• On August 5, 2026 Mirum Pharmaceuticals, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2026. The full press release is furnished as Exhibit 99.1 to the Form 8‑K. The Form 8‑K notes that the furnished material is not “filed” under Section 18 of the Exchange Act. The report was signed by CEO Christopher Peetz.

Key Details

• Filing date: August 5, 2026.
• Reporting period: quarter ended June 30, 2026 (quarterly results / earnings announced in press release).
• Press release furnished as Exhibit 99.1 to the Form 8‑K (consult exhibit for the detailed revenue, earnings and other financial metrics).
• Form 8‑K states the furnished information is not deemed “filed” for Section 18 liability and is not automatically incorporated by reference into other SEC filings.

Why It Matters

• This 8‑K notifies investors that Mirum has released its quarterly results and a corporate update; investors should read the Exhibit 99.1 press release to see the company's reported revenue, earnings, cash position, and any guidance or operational commentary.
• The filing’s “furnished, not filed” status is a legal/technical note—useful to know for disclosure/liability context—but does not change the need to review the announced quarterly results for investment decisions.